Cardioprotective effects of defibrotide in acute myocardial ischemia in the cat.
We investigated the effects of Defibrotide (D), a natural polydeoxyribonucleotide, on acute myocardial ischemia (AMI) in anesthetized cats. A permanent ligature was placed around the left anterior descending coronary artery (LAD) 12-14 mm from its origin. Ventricular fibrillation and death were exceptional and when they occurred the cats were not included in the evaluation. Pretreatment of cats with D, 32 mg Kg-1 h-1, i.v. infusion, maintained throughout the 5 h occlusion period, reduced AMI-ST segment increases and increased the diminished pressure-rate index (PRI). AMI-induced changes in lactate, ATP and CPK in ischemic tissue were prevented by D. PGI2 gave the same results as D. Atenolol prevented the loss of myocardial CPK, but had no favourable effects on lactate and ATP in ischemic tissue. The beneficial effects of D in AMI reported here could be partly attributed to its ability to enhance PGI2 release from vascular walls; D might also relieve ischemia by improvement of local tissue oxygenation, energy supplies and platelet function by its ability to deaggregate platelet clumps.
D000208:Acute Disease; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001262:Atenolol / Q000627:therapeutic use; D002415:Cats; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D003402:Creatine Kinase / Q000378:metabolism; D004562:Electrocardiography; D011464:Epoprostenol / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006439:Hemodynamics; D007773:Lactates / Q000378:metabolism; D008297:Male; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism*; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D007773:Lactates; D011089:Polydeoxyribonucleotides; C036901:defibrotide; D001262:Atenolol; D000255:Adenosine Triphosphate; D011464:Epoprostenol; D003402:Creatine Kinase